Vaccine race all but over; should we still invest in local capability?
Successful vaccine developers have reaped massive benefits, so what’s become of New Zealand’s early investments?
Julie Iles
Mon, 22 Feb 2021
In the race to the Covid-19 vaccine, the progress that has now led to New Zealand’s first jab on Friday has seen several of the biotech world’s largest players fall flat, while others that had never had a vaccine approved before have rocketed into the global consciousness.
Shares in GSK,
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
NZ Aviation News
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Aviation News - Monthly
NZ$14.95 / monthly
Already have an account? Login
Julie Iles
Mon, 22 Feb 2021
Contact the Writer: julie@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Vaccine race all but over; should we still invest in local capability?
Business,
86411